Vortioxetine for Depression in Adults

  title={Vortioxetine for Depression in Adults},
  author={JoAnn D Long},
  journal={Issues in Mental Health Nursing},
  pages={819 - 820}
  • J. Long
  • Published 21 June 2019
  • Psychology
  • Issues in Mental Health Nursing
An estimated 300 million people worldwide are affected by major depressive disorder. The severity of symptoms associated with depression varies considerably affecting the entire person. Major depre... 

Recent advances in the psychopharmacology of major depressive disorder

Evidence is synthesised on emerging pharmacological therapies targeting the serotonergic system, before exploring several novel treatment targets: the glutamatergic system, the GABAergic system and inflammation.

▼ Vortioxetine for acute depression in adults

  • Psychology
    Drug and Therapeutics Bulletin
  • 2017
A Cochrane review has assessed the efficacy and acceptability of vortioxetine compared with placebo and other antidepressant drugs in the treatment of acute depression in adults.

Vortioxetine for depression: the evidence for its current use in the UK

The Cochrane Corner review examines the evidence available for the use of vortioxetine as a first-line treatment for depression in adults and puts the findings into their clinical context and revises them in view of earlier and later studies.

What Is New about New Antidepressants?

  • S. Dubovsky
  • Psychology, Medicine
    Psychotherapy and Psychosomatics
  • 2018
How realistic this expectation of each new antidepressant that reaches the market will represent a conceptual and therapeutic advance over previous medications is determined if the validity of the assumptions that underlie the development of new antidepressants and the data supporting their differential effectiveness are reviewed.

Skin Side Effects Due To Vortioxetine Case Series

This study reports three different cases in which dermatological side effects developed after treatment with vortioxetine, a new generation antidepressant approved for the treatment of Major Depressive Disorder (MDD).

Cognitive impairment in depression: recent advances and novel treatments

This review considers the different issues, in terms of disease evolution, raised by the presence of cognitive disorders associated with depression and considers, particularly from the neurologist’s perspective, the ways in which the clinical approach to cognitive symptoms, and their interpretation to diagnostic and therapeutic ends, have changed in recent years.

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults

Vortioxetine is more advantageous over placebo in treating MDD among adults, but no significant difference compared to SNRIs and SSRIs in general.

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression

VTX can be a valid therapeutic choice for patients with BED with comorbid depression in controlling the depressive symptoms, working memory, and eating behavior, and confirms the results already obtained with VTX in other disorders.

Key considerations in the pharmacological management of treatment-resistant depression

This manuscript reviews evidence-based treatment strategies for the clinical management of treatment-resistant depression and suggests robust biomarkers that could one day be integrated into clinical practice has the potential to advance specific treatment targets and ultimately improve treatment and remission outcomes.

Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial

WhetherAdd-on simvastatin to standard antidepressant medication with escitalopram is more efficacious than add-on placebo over 12 weeks in 160 patients with MDD and comorbid obesity is determined.



Vortioxetine for depression in adults

Vortioxetine may be more effective than placebo across the three efficacy outcomes: response (Mantel-Haenszel RR 1.35, 95% CI 1.22 to 1.49; 14 studies, 6220 participants), remission (RR 1.32, 95%).


This guideline recommends screening adults for depression in clinical practices that have "systems in place to assure accurate diagnosis, effective treatment, and follow-up" and advises clinicians to consider screening patients with identified risk factors and those with several unexplained or unrelated somatic symptoms.